Updates
-
-
NovoSeven Linked to Low Rate of Dangerous Blood Clots in Review Study
Problematic thrombotic events are fairly rare in people using NovoSeven, among all types of bleeding disorders for which it is approved, including hemophilia, a review ... Read more -
The Unwritten Rules of Processing Information
One of my favorite educational philosophers is Ruby Payne. Payne focuses on the unwritten rules of social classes and how various groups respond to ... Read more -
Cutting Remarks Can Harm Those with Invisible Illness
My mighty warrior, Caeleb, has been in great health for the past five years. Five years of the occasional ear infection, strep throat, or ... Read more -
NovoSeven-Hemlibra Combo Not Linked to Higher Risk of Thrombosis, Data Show
Simultaneous use of NovoSeven (recombinant factor VIIa, rFVIIa) and Hemlibra (emicizumab) in patients with hemophilia A is not associated with higher risk of ... Read more -
Life Between Peak and Trough
One of the challenges for individuals with hemophilia — whether severe, moderate, or mild — is bleeds. Often people with hemophilia will struggle with ... Read more
-
Your Joint Health Is Important
Submitted by Takeda Every joint bleed matters 70% to 80% of all bleeds in ... -
A Little Money Is a Big Deal When a Partner Has a Disability
I lost some money today during an online transaction. It was 3,150 Philippine pesos ... -
Study: Hemlibra Is Safe, Effective in Young Hemophilia A Patients Without Inhibitors
Hemlibra (emicizumab) is safe and effective to treat children younger than 12 who have hemophilia ... -
Freeline’s Gene Therapy for Hemophilia B Is Promising, Phase 1/2 Data Show
Data from the first two patients treated with FLT180a, Freeline’s single-infusion gene therapy for patients ... -
Subscribe to our mailing list
Get regular updates delivered to your email box.
Thanks! Please check your email for a confirmation email.
Europe’s CHMP Recommends Approval of Hemlibra to Treat Hemophilia A
News
Europe’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion supporting the approval of Hemlibra (emicizumab) for routine prophylaxis of bleeding episodes in hemophilia A patients with factor VIII inhibitors. Hemlibra is a humanized monoclonal antibody that ... Read more